These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 20182024)

  • 21. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.
    Castro AA; Ghisoni K; Latini A; Quevedo J; Tasca CI; Prediger RD
    Behav Brain Res; 2012 Apr; 229(1):208-15. PubMed ID: 22266923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroprotection in Parkinson's disease.
    Schapira AH
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S41-3. PubMed ID: 20123556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. When does Parkinson's disease begin?
    Gaig C; Tolosa E
    Mov Disord; 2009; 24 Suppl 2():S656-64. PubMed ID: 19877243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfactory dysfunction in Parkinson's disease.
    Kranick SM; Duda JE
    Neurosignals; 2008; 16(1):35-40. PubMed ID: 18097158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of Parkinson disease. 1: Standard therapy of motor and non-motor symptoms].
    Kuhn W; Müller T
    Fortschr Neurol Psychiatr; 1997 Aug; 65(8):361-74. PubMed ID: 9378449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
    Vale S
    Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rasagiline: effectiveness and protection in Parkinson's disease].
    Pagonabarraga J; Kulisevsky J
    Rev Neurol; 2010 Nov; 51(9):535-41. PubMed ID: 20979033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in the clinical expression of Parkinson's disease.
    Wolters ECh
    J Neurol Sci; 2008 Mar; 266(1-2):197-203. PubMed ID: 17854836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.
    Liu WG; Lu GQ; Li B; Chen SD
    Parkinsonism Relat Disord; 2007 Mar; 13(2):77-88. PubMed ID: 16963309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Future drug targets for Parkinson's disease].
    Hirsch EC
    Bull Acad Natl Med; 2012 Oct; 196(7):1369-77; discussion 1377-9. PubMed ID: 23815021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. When does Parkinson's disease begin? From prodromal disease to motor signs.
    Meissner WG
    Rev Neurol (Paris); 2012 Nov; 168(11):809-14. PubMed ID: 22981298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.